Use of Insulin-Sensitizing Agents in Patients With Polycystic Ovary Syndrome

In 2001, a review article highlighted the potential benefits of insulin-sensitizing agents for women with Polycystic Ovary Syndrome (PCOS). The review indicated that metformin, an insulin sensitizer, was associated with improved ovulatory cycling in 56% of patients, weight loss, and reduced testosterone levels. Although troglitazone also had positive effects, it was less effective than metformin and is no longer in clinical use. D-chiro-inositol was another agent that showed promise in improving insulin sensitivity and ovulatory rates. Despite these positive findings, the review called for larger multicenter studies to confirm the results, as not all PCOS patients are insulin resistant and the effectiveness of these treatments can vary. The document also included specific study results, such as one where 12 out of 35 patients treated with metformin ovulated spontaneously, compared to only 1 in the control group, and another where metformin improved menstrual regularity and decreased free testosterone levels. The need for caution in using these agents and further research into other thiazolidinediones was also emphasized.